Market research
MEDCL.PA MedinCell S.A
PA EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 945M
- P/E ratio
- Not available
- Analyst target
- 35.5111
- Dividend yield
- Not available
- Beta
- 0.92
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0004065605
- Market cap
- 945M
- P/E ratio
- Not available
- Analyst target
- 35.5111
- Dividend yield
- Not available
- Beta
- 0.92
About
About MedinCell S.A
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
Research context
MedinCell S.A appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MEDCL.PA discussion.
5 years, 6 months ago
MedinCell S.A is currently in a long term downtrend where the price is trading 18.1% below its 200 day moving average.
From a valuation standpoint, the stock is 58.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 112.3.
MedinCell S.A's total revenue sank by 0.0% to $2M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.3% to $-3M since the same quarter in the previous year.
Based on the above factors, MedinCell S.A gets an overall score of 2/5.